Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Sevelamer Carbonate Dry Suspension

Stock News

06/01

Shandong Xinhua Pharmaceutical Co., Ltd. has announced that it recently obtained the Drug Registration Certificate for Sevelamer Carbonate Dry Suspension from the National Medical Products Administration.

This product is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis, as well as for adult CKD patients with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis.

The approval of Sevelamer Carbonate Dry Suspension enhances the company's portfolio of preparation products and is expected to strengthen its overall competitiveness in the market.

**Shandong Xinhua (00719)**

The company's recent regulatory milestone adds a new therapeutic option to its product lineup, supporting its position in the pharmaceutical industry.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1156155531"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156155531\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156155531?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156155531","market":"nz","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Sevelamer Carbonate Dry Suspension","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical Co., Ltd. has announced that it recently obtained the Drug Registration Certificate for Sevelamer Carbonate Dry Suspension from the National Medical Products Administration.<br><br>This product is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis, as well as for adult CKD patients with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis.<br><br>The approval of Sevelamer Carbonate Dry Suspension enhances the company's portfolio of preparation products and is expected to strengthen its overall competitiveness in the market.<br><br>**Shandong Xinhua (00719)**<br><br>The company's recent regulatory milestone adds a new therapeutic option to its product lineup, supporting its position in the pharmaceutical industry.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Sevelamer Carbonate Dry Suspension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Sevelamer Carbonate Dry Suspension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Co., Ltd. has announced that it recently obtained the Drug Registration Certificate for Sevelamer Carbonate Dry Suspension from the National Medical Products Administration.<br><br>This product is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis, as well as for adult CKD patients with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis.<br><br>The approval of Sevelamer Carbonate Dry Suspension enhances the company's portfolio of preparation products and is expected to strengthen its overall competitiveness in the market.<br><br>**Shandong Xinhua (00719)**<br><br>The company's recent regulatory milestone adds a new therapeutic option to its product lineup, supporting its position in the pharmaceutical industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1156155531","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156155531","pubTimestamp":1780303886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical Co., Ltd. has announced that it recently obtained the Drug Registration Certificate for Sevelamer Carbonate Dry Suspension from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","00719":"山东新华制药股份"},"translate_title":"山东新华制药获得碳酸司维拉姆干混悬剂药品注册证书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Co., Ltd. has announced that it recently obtained the Drug Registration Certificate for Sevelamer Carbonate Dry Suspension from the National Medical Products Administration.This product is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis, as well as for adult CKD patients with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis.The approval of Sevelamer Carbonate Dry Suspension enhances the company's portfolio of preparation products and is expected to strengthen its overall competitiveness in the market.**Shandong Xinhua (00719)**The company's recent regulatory milestone adds a new therapeutic option to its product lineup, supporting its position in the pharmaceutical industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}